Skip to main content

Table 1 Demographics, anthropometry and prevalence of atopy according to randomization group

From: Vitamin A supplementation and risk of atopy: long-term follow-up of a randomized trial of vitamin A supplementation at six and nine months of age

 

VAS (n = 137)

Placebo (n = 137)

P value or PR (95% CI)

At enrolment

   

 Age (days)

200 (183–294) n = 137

198 (183–301) n = 137

0.93

 Weight (kg)

7.1 (6.1-8.7) n = 88

7.5 (5.9-8.8) n = 79

0.35

 MUAC (mm)

144 (126–160) n = 86

144 (130–166) n = 80

0.99

 Breastfeeding

86/94 (91%)

80/90 (89%)

0.55

 DTP3 vaccinated

84/137 (61%)

95/137 (69%)

0.16

At follow up

   

 Age (years)

7.4 (7.0-7.7) n = 137

7.4 (7.0-7.7) n = 137

0.72

 Weight (kg)

20.0 (17.0-24.0) n = 136

20.5 (17.0-23.5) n = 137

0.78

 Height (cm)

119 (112–126) n = 137

118 (111–125) n = 137

0.46

 MUAC (mm)

166 (150–184) n = 137

166 (152–180) n = 137

0.77

 BCG scar

105/132 (80%)

110/131 (84%)

0.35

 Pig at the house

43/134 (32%)

47/133 (35%)

0.57

Atopy in all children (n = 263)

22/131 (17%)

18/132 (14%)

1.23 (0.69-2.18)

Atopy stratified by sex

   

 Boys (n = 135)

11/67 (16%)

7/68 (10%)

1.60 (0.66-3.90)

 Girls (n = 128)

11/64 (17%)

11/64 (17%)

1.00 (0.46-2.15)

  1. VAS = vitamin A supplementation; PR = prevalence ratio adjusted for age and sex; MUAC = mid-upper arm circumference; DTP3 = 3rd dose of diphtheria-tetanus-whole cell pertussis vaccine due at 14 weeks of age.